Maintenance of Long-Term Effective Humoral Immune Response in Patients with COVID-19 with Homologous or Heterologous Booster Vaccines: A Retrospective Study
Viral Immunology · 2024
DOI: 10.1089/vim.2024.0076 ↗At a glance
Journal article in Viral Immunology, 2024. Written by Xin Zhang and 14 co-authors. Institution: Department of Infectious Disease, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Major MEDLINE topics: Immunization, Secondary, COVID-19, COVID-19 Vaccines, Antibodies, Viral. 33 references.
Abstract (original language)
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and first identified in Wuhan, China, in December 2019, has led to global efforts in vaccination to mitigate rising morbidity and mortality, with vaccines proving crucial in controlling the pandemic. This study evaluated the humoral responses to the inactivated virus vaccine Sinopharm or Koxing Kerlafor, the protein subunit vaccine ZF001, and the adenoviral vector vaccine Convidecia after 18 months of inactivated virus vaccination by heterologous and homologous booster vaccination in patients with previous SARS-CoV-2 infection and healthy individuals. We discovered that patients who had recovered from the infection and then received a third vaccine dose (booster) exhibited durable immunity. Furthermore, the heterologous booster vaccine induced higher neutralizing antibody responses compared with the homologous booster. These findings offer valuable insights into the efficacy of different COVID-19 vaccine strategies following booster immunization.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Infectious Disease, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Department of Tuberculosis, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, Hebei, China.
- Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, China.
- Intensive Care Unit, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, Hebei, China.
- Department of Clinical Laboratory, State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
- Department of Orthopedics, The Fourth Hospital of Hebei Medical University and Hebei Cancer Hospital, Shijiazhuang, Hebei, China.
ORCID profiles: Xin Zhang
Cite
APA
Zhang, X., Li, L., Liu, Y., Zhan, H., Dai, M., Zhang, K., Yan, H., Gao, H., Liu, J., Liu, S., Lu, W., Li, Y., Feng, A., Dai, E., & Zhou, J. (2024). Maintenance of Long-Term Effective Humoral Immune Response in Patients with COVID-19 with Homologous or Heterologous Booster Vaccines: A Retrospective Study. Viral Immunology. https://doi.org/10.1089/vim.2024.0076
Vancouver
Zhang X, Li L, Liu Y, Zhan H, Dai M, Zhang K, et al. Maintenance of Long-Term Effective Humoral Immune Response in Patients with COVID-19 with Homologous or Heterologous Booster Vaccines: A Retrospective Study. Viral Immunology. 2024. doi:10.1089/vim.2024.0076
BibTeX
@article{Zhang2024,
author = {Zhang, Xin and Li, Li and Liu, Yongmei and Zhan, Haoting and Dai, Muwei and Zhang, Kun and Yan, Huimin and Gao, Huixia and Liu, Jingwen and Liu, Shifu and Lu, Weina and Li, Yongzhe and Feng, Aidong and Dai, Erhei and Zhou, Junying},
title = {Maintenance of Long-Term Effective Humoral Immune Response in Patients with COVID-19 with Homologous or Heterologous Booster Vaccines: A Retrospective Study},
journal = {Viral Immunology},
year = {2024},
doi = {10.1089/vim.2024.0076}
}
EUVIMED